Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) as Milestone Drives 1Q Beat
May 10, 2016 6:43 AM EDTMizuho Securities reiterated a Buy rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $16.00 (from $15.00), following the company's 1Q earnings report. IRWD reported $66M in revenues and loss of ($0.08) per share, both ahead of consensus estimates of $53.6M and ($0.14). The beat can be... More
Ironwood Pharma (IRWD) Tops Q1 EPS by 6c
May 9, 2016 4:17 PM EDTIronwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.08), $0.06 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $66 million versus the consensus estimate of $53.58 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More